IQVIA Holdings Inc. $IQV Shares Sold by Invera Wealth Advisors LLC

Invera Wealth Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,142 shares of the medical research company’s stock after selling 3,078 shares during the period. IQVIA accounts for about 1.3% of Invera Wealth Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. Invera Wealth Advisors LLC’s holdings in IQVIA were worth $2,116,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its position in IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after acquiring an additional 53 shares during the period. Private Trust Co. NA lifted its holdings in IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after purchasing an additional 67 shares during the period. E Fund Management Co. Ltd. grew its position in IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after buying an additional 74 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock valued at $531,000 after buying an additional 78 shares during the period. Finally, Hemington Wealth Management raised its position in shares of IQVIA by 43.4% during the 3rd quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock worth $49,000 after buying an additional 79 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. TD Cowen downgraded IQVIA from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. BMO Capital Markets started coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Trading Down 1.3%

Shares of IQV opened at $238.03 on Monday. The business’s 50-day moving average price is $227.30 and its 200 day moving average price is $203.61. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $40.54 billion, a P/E ratio of 32.65, a P/E/G ratio of 2.42 and a beta of 1.36. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same period last year, the company posted $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.